Search

Your search keyword '"A. Tiberghien"' showing total 358 results

Search Constraints

Start Over You searched for: Author "A. Tiberghien" Remove constraint Author: "A. Tiberghien" Topic humans Remove constraint Topic: humans
358 results on '"A. Tiberghien"'

Search Results

1. Neutralizing IFN-γ autoantibodies are rare and pathogenic in HLA-DRB1*15:02 or 16:02 individuals.

2. HIV transmission network analysis allows identifying unreported risk factors in HIV‐positive blood donors in France

3. Blood donor eligibility criteria for medical conditions: A <scp>BEST</scp> collaborative study

4. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies

5. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination

6. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

7. Inflammatory profile of convalescent plasma to treat COVID: Impact of amotosalen/UVA pathogen reduction technology

8. Decoding the Human Genetic and Immunological Basis of COVID-19 mRNA Vaccine-Induced Myocarditis

9. Autoantibodies against type I IFNs in patients with critical influenza pneumonia

10. Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

11. Early Post-Transplant Red Blood Cell Transfusion Is Associated With an Increased Risk of Transplant Failure: A Nationwide French Study

13. The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors

14. Processing methods and storage duration impact extracellular vesicle counts in red blood cell units

15. Trends in platelet distributions from 2008 to 2017: a survey of twelve national and regional blood collectors

16. Transfusion of Uncrossmatched Group O Erythrocyte-containing Products Does Not Interfere with Most ABO Typings

17. Convalescent plasma therapy for B-cell–depleted patients with protracted COVID-19

18. Reduced neutralizing antibody potency of COVID ‐19 convalescent vaccinated plasma against SARS‐CoV ‐2 Omicron variant

19. Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis

20. COVID‐19 convalescent plasma: Evolving strategies for serological screening in France

21. The transfusion of non-prophylactically RH-KEL1 antigen-matched red blood cells is feasible in selected myelodysplastic syndrome and acute myeloid leukaemia patients

22. The impact of pathogen-reduced platelets in acute leukaemia treatment on the total blood product requirement: a subgroup analysis of an EFFIPAP randomised trial

23. Electrocardiographic abnormalities in COVID-19 patients visiting the emergency department: a multicenter retrospective study

24. An international comparison of HIV prevalence and incidence in blood donors and general population: a BEST Collaborative study

26. Autoantibodies neutralizing type I IFNs are present in

27. Rational and design of the T-STORHM Study: A prospective randomized trial comparing fresh whole blood to blood components for acutely bleeding trauma patients

28. Transfusion-Transmitted Hepatitis E Virus Infection in France

29. International haemovigilance: what have we learned and what do we need to do next?

30. Maternal HLA-G*01:01:01:04 protects from anti-HLA-class II immunization in pregnant women

31. International Forum on the Collection and Use of COVID‐19 Convalescent Plasma: Protocols, Challenges and Lessons Learned: Summary

32. Lessons learned in the collection of convalescent plasma during the COVID‐19 pandemic

33. Preventing transfusion-transmitted malaria in France

34. A look-back at convalescent plasma to treat COVID-19

35. Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries

36. Risk for Hepatitis E Virus Transmission by Solvent/Detergent-Treated Plasma

37. A single dose of antibody-drug conjugate cures a stage 1 model of African trypanosomiasis

38. No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation

39. Potential human transmission of amyloid β pathology: surveillance and risks

40. Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19

41. Platelet transfusions in haematologic malignancies in the last six months of life

42. Collecting and evaluating convalescent plasma for COVID‐19 treatment: why and how?

43. Variations in hemoglobin measurement and eligibility criteria across blood donation services are associated with differing low-hemoglobin deferral rates: a BEST Collaborative study

44. Variations in hemoglobin measurement and eligibility criteria across blood donation services are associated with differing low-hemoglobin deferral rates: a BEST Collaborative study

45. Sugar intake and craving during alcohol withdrawal in alcohol use disorder inpatients

46. Donor-targeted serotherapy as a rescue therapy for steroid-resistant acute GVHD after HLA-mismatched kidney transplantation

47. Convalescent plasma to treat COVID-19: Following the Argentinian lead

48. Localized neuropathic pain: an expert consensus on local treatments

49. An assessment of differences in costs and health benefits of serology and NAT screening of donations for blood transfusion in different Western countries

50. Synthesis and in vitro evaluation of SG3227, a pyrrolobenzodiazepine dimer antibody-drug conjugate payload based on sibiromycin

Catalog

Books, media, physical & digital resources